Holistic care improves outcomes for hypoparathyroidism patients

Chronic hypoparathyroidism (HypoPTH) is a rare condition caused by low levels of parathyroid hormone, affecting calcium and phosphate regulation. Traditional treatment focuses on calcium normalization, often neglecting broader patient needs and symptoms, leading to poor quality of life. In 2024, the FDA approved palopegteriparatide, a new hormone therapy for HypoPTH. In clinical trials, 79% of patients using this treatment met key health goals, compared to only 5% in the placebo group, marking a significant advancement in managing the disease. A holistic approach is now emphasized, addressing physical and psychological aspects of HypoPTH. Healthcare providers are encouraged to engage with patients about their symptoms and quality of life, ensuring comprehensive care beyond just calcium levels.